Boom Or Bust: Where Does Summit Therapeutics Inc. (NASDAQ: SMMT) Stock Go From Here? – Marketing Sentinel
Home  »  Technologies   »  Boom Or Bust: Where Does Summit Therapeutics Inc. ...

Boom Or Bust: Where Does Summit Therapeutics Inc. (NASDAQ: SMMT) Stock Go From Here?

During the last session, Summit Therapeutics Inc. (NASDAQ:SMMT)’s traded shares were 1.08 million, with the beta value of the company hitting 1.11. At the end of the trading day, the stock’s price was $1.13, reflecting an intraday gain of 4.63% or $0.05. The 52-week high for the SMMT share is $8.39, that puts it down -642.48 from that peak though still a striking 22.12% gain since the share price plummeted to a 52-week low of $0.88. The company’s market capitalization is $111.50M, and the average trade volume was 120.69K shares over the past three months.

Summit Therapeutics Inc. (NASDAQ:SMMT) trade information

Summit Therapeutics Inc. (SMMT) registered a 4.63% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.63% in intraday trading to $1.13 this Thursday, 06/23/22, hitting a weekly high. The stock’s 5-day price performance is 14.55%, and it has moved by 17.04% in 30 days. Based on these gigs, the overall price performance for the year is -82.53%.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


The consensus price target of analysts on Wall Street is $4.00, which implies an increase of 71.75% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4.00 and $4.00 respectively. As a result, SMMT is trading at a discount of -253.98% off the target high and -253.98% off the low.

Summit Therapeutics Inc. (SMMT) estimates and forecasts

In the rating firms’ projections, revenue will decrease -92.30% compared to the previous financial year.

As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $4.55 million and $192k respectively.

While earnings are projected to return -26.70% in 2022.

SMMT Dividends

Summit Therapeutics Inc. is due to release its next quarterly earnings between March 15 and March 21. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Summit Therapeutics Inc. (NASDAQ:SMMT)’s Major holders

Summit Therapeutics Inc. insiders own 73.81% of total outstanding shares while institutional holders control 11.23%, with the float percentage being 42.89%. Polar Capital Holdings Plc is the largest shareholder of the company, while 87 institutions own stock in it. As of Dec 30, 2021, the company held over 6.12 million shares (or 6.23% of all shares), a total value of $16.46 million in shares.

The next largest institutional holding, with 1.37 million shares, is of Blackrock Inc.’s that is approximately 1.39% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $3.34 million.

Also, the Mutual Funds coming in first place with the largest holdings of Summit Therapeutics Inc. (SMMT) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Dec 30, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 0.73 million shares. This amounts to just over 0.75 percent of the company’s overall shares, with a $1.97 million market value. The same data shows that the other fund manager holds slightly less at 0.52 million, or about 0.53% of the stock, which is worth about $1.14 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts